Like Decision Resources Group

closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
announced 1/22/2020 via PR Newswire

Clarivate Analytics, will acquire Decision Resources Group

synopsis: Clarivate Analytics plc, a global leader in providing trusted insights and analytics, will acquire Decision Resources Group ("DRG"), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, from Piramal Enterprises Limited, part of global business conglomerate Piramal Group.
buyer: Clarivate Analytics (:$964.58)
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management. "
target parent: Piramal Group
target: Decision Resources Group
Decision Resources Group (DRG) is uniquely positioned to help healthcare businesses improve the lives of patients around the world by creating patient-centric commercial strategies that drive better outcomes and better access.
price ($mm)
$950
rev ($mm)
$207
EBITDA ($mm)
$48
EV / rev
4.6x
EV / EBITDA
20.0x
closed 5/21/2019 via BusinessWire

Xcenda, acquired Dymaxium, Inc.

synopsis: Xcenda, a part of AmerisourceBergen, announced the acquisition of Dymaxium, a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
buyer parent: AmerisourceBergen Corporation
buyer: Xcenda
Xcenda, part of AmerisourceBergen, is a strategic consultancy with 20+ years of experience applying real-world expertise in health economics and outcomes research, reimbursement, stakeholder insights, and market access consulting and communications. "
target: Dymaxium, Inc.
Dymaxium is a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2016 via BNC Analysis

M3, Inc., will acquire Vidal Group

synopsis: Electra Partners’ portfolio company AXIO Group has received a binding offer from M3 Inc. to purchase Vidal Group, a European provider of reference drug information. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients with on-line access to up-to-date drug databases and related treatment-based information.
buyer: M3, Inc. (TSE:2413:$1,127.03)
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet. "
target parent: Electra Partners LLP
target: Vidal Group
Vidal Group is a leading European healthcare informatics and information systems company. Vidal Group provides hospitals, primary care physicians, pharmacists, and patients across Europe with on-line access to up-to-date drug databases and related treatment-based information.
price ($mm)
$133
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/30/2016 via BNC Analysis

Affinity Equity Partners, will acquire MedicalDirector

synopsis: Leading Asian private equity firm Affinity Equity Partners agreed to acquire Sydney-based MedicalDirector (formerly Health Communication Network) from Australia’s Primary Health Care Ltd. MedicalDirector is a leading provider of clinical and enterprise software solutions to general practitioners, medical specialists and allied health professionals.
buyer: Affinity Equity Partners
Affinity Equity Partners is an independently-owned buyout fund manager comprising primarily the former investment professionals of UBS Capital Asia Pacific. They are pioneers in buyout investments in the Asia-Pacific region, with an established and widely recognised franchise. "
target parent: Primary Health Care Limited
target: MedicalDirector
MedicalDirector has been supporting healthcare professionals and improving health outcomes for more than 20 years. They provide software for practice management, optimizing patient outcomes, and access to Australia's most comprehensive and up-to-date pharmaceutical database.
price ($mm)
$119
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 8/26/2015 via Company Press Release

Inovalon, Inc., will acquire Avalere Health LLC

synopsis: Inovalon, a leading technology company providing cloud-based analytics and data-driven intervention platforms to the healthcare industry, has entered into a definitive agreement to acquire Avalere Health, Inc., a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
buyer: Inovalon, Inc. (INOV:$449.36)
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. "
target: Avalere Health LLC
Avalere Health, Inc. is a leading provider of data-driven advisory services and business intelligence solutions to the pharmaceutical and life sciences industry.
price ($mm)
$140
rev ($mm)
$47
EBITDA ($mm)
EV / rev
3.0x
EV / EBITDA
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/22/2010 via Company Press Release

CT Corsearch, acquired Edital

synopsis: CT Corsearch, the premier provider of clearance and protection solutions for trademark and brand professionals, announced it’s acquired Edital, the Questel trademark branch. This acquisition will create best-in-class solutions for managing a brand lifecycle globally—from creation to watching to protecting, maintaining and renewing a brand.
buyer parent: Wolters Kluwer NV
buyer: CT Corsearch
CT Corsearch provides high-quality, intuitive tools and expertise that trademark professionals need to effectively manage the trademark screening, search review and watching processes. "
target parent: Questel
target: Edital
Edital was established in Brussels in 1982 and acquired by Questel, a world leader in Intellectual Property in 2005. Its sole purpose has been to create global solutions for the Intellectual Property professional.
price ($mm)
rev ($mm)
$8
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 9/27/2007 via PR Newswire

Thomson Pharma, acquired Prous Science

synopsis: The Thomson Corporation, a leading provider of information solutions to business and professional customers worldwide, today announced that it has acquired Prous Science, a global leader in the provision of life sciences information solutions. Prous Science will become part of Thomson Scientific.
buyer parent: The Thomson Corporation
buyer: Thomson Pharma (:$964.58)
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: Prous Science
Prous Science is a trusted source of information on which science depends to discover safer and more effective medicines. The company's products have evolved through the years from print journals to sophisticated electronic products incorporating the latest advances in IT.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2007 via Company Description

MergerMarket, acquired Infinata, Inc.

synopsis: In September 2007, Mergermarket acquired Infinata, an information solutions and marketing analytics provider to the global financial service, life science, and high technology industries.
buyer parent: Pearson plc
buyer: MergerMarket
MergerMarket, part of Pearson's Financial Times Group, is an unparalleled, independent M&A intelligence tool used by the world's foremost financial institutions to originate deals. It provides proprietary intelligence on potential deal flow, potential mandates and valuations. "
target: Infinata, Inc.
Infinata is an innovative provider of information solutions and marketing analytics to the global financial service, life science, and high-tech industries. Our information suites include: BioPharm Insight, High Net Worth Insight, and Corporate Tracker.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/7/2019 via BNC Analysis

Inflexion Private Equity Partners LLP, will acquire Pharmaspectra

synopsis: Inflexion Private Equity, a UK mid-market private equity firm, will acquire Pharmaspectra, a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature.
buyer: Inflexion Private Equity Partners LLP
Inflexion is a UK mid-market private equity firm. They invest in high growth, entrepreneurial businesses and work with them to accelerate growth. Inflexion’s flexible approach allows it to back both majority and minority investments, typically investing £10m to £150m of equity in each deal. "
target: Pharmaspectra
Pharmaspectra is a global provider of medical affairs data to the pharmaceutical and biotech industry. Pharmaspectra offers the world's largest database for medical scientific literature and biomedical literature. Their web-based solutions analyze data across the entire medical continuum.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/3/2013 via Company Press Release

JISC Collections, acquired SpringerProtocols

synopsis: Springer announced that JISC Collections has purchased the archive content of SpringerProtocols; the world’s largest database of life sciences protocols. SpringerProtocols contains more than 31,000 protocols, most of which come from the classic book series “Methods in Molecular Biology”.
buyer: JISC Collections
JISC Collections supports the procurement of digital content for education and research in the UK. They are uniquely placed to provide members with: expertise in negotiating and procurement, within the scholarly communications sector. "
target parent: EQT
target: SpringerProtocols
SpringerProtocols combines the world’s largest collection of life sciences and bio-medicine protocols with advanced search functionality. Used primarily in the life sciences, the protocols provide sets of instructions that allow scientists to recreate experiments in their own laboratories.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 2/7/2013 via Wall Street Journal

Wilmington Group plc, acquired NHiS Ltd

synopsis: Wilmington Group plc, the provider of Information, Compliance, and Education to professional markets announced the acquisition of the entire issued and to be issued share capital of NHiS Limited. NHiS is a leading provider of business intelligence, data analysis, workflow tools and other services to pharmaceutical companies in the UK.
buyer: Wilmington Group plc (LSE:WIL:$162.62)
Wilmington Group plc is a dynamic and expanding company providing information and training to professional business markets. Their businesses enable professionals and their organizations to perform better by providing quality, relevant and reliable information, education and knowledge. "
target: NHiS Ltd
NHiS is the leading provider of market intelligence and insight to the pharmaceutical sector. NHiS’s products assist organizations in their understanding, engagement and optimization of their markets.
price ($mm)
$8.82
rev ($mm)
$3
EBITDA ($mm)
EV / rev
5.2x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
closed 9/13/2011 via PR Newswire

ImpactRx, Inc., acquired TargetRx, Inc.

synopsis: ImpactRx, a Symphony Technology Group company and the pioneer in measuring the impact of promotion on physician prescribing behavior, announced that it has acquired 100% of TargetRx, Inc., a leading provider of insight into the drivers of physician behavior for pharmaceutical companies.
buyer parent: Symphony Technology Group
buyer: ImpactRx, Inc.
ImpactRx is the leading provider of consultative and analytically-based promotional effectiveness solutions to the healthcare industry. ImpactRx's ImpactData™ is the industry’s sole source of continuous-capture market promotion and physician treatment data. "
target: TargetRx, Inc.
TargetRx, Inc. is a leading provider of insight into the drivers of physician behavior for pharmaceutical companies. The company offers a suite of solutions from pipeline to patent expiry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/3/2016 via PR Newswire

IMS Health Incorporated, acquired AlphaImpactRx, Inc

synopsis: Symphony Technology Group announced the closing of the sale of AlphaImpactRx, a leading provider of primary research and analytics-based insight for biopharmaceutical and consumer health companies to IMS Health, a global information and technology services company serving the healthcare industry.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target parent: Symphony Technology Group
target: AlphaImpactRx, Inc
AlphaImpactRx is the leading provider of primary research-based insights, analytics and solutions to pharmaceutical, consumer health and medical device companies. They provide market research to help its global healthcare clients make informed and business decisions to market their products.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/18/2011 via PR Newswire

Symphony Technology Group, acquired ImpactRx, Inc.

synopsis: ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior, announced that Symphony Technology Group (STG), has acquired a majority ownership interest in the Company. STG is a leading private equity firm with a strategic focus on data, analytics and technology-enabled services companies.
buyer: Symphony Technology Group
Symphony Technology Group (STG) is a strategic private equity firm with the mission of investing in and building great software and services companies. STG also provides transformation expertise to enable its companies to deliver maximum value to its clients. "
target: ImpactRx, Inc.
ImpactRX annually captures three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx leverages this unprecedented intelligence with custom research and analytics to provide insightful solutions to pharmaceutical marketing and sales decision makers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/26/2020 via PR Newswire

Arsenal Capital Partners, acquired BresMed Health Solutions Ltd

synopsis: Arsenal Capital Partners, a leading private equity firm investing in healthcare and specialty industrials companies, announced the acquisition of BresMed Health Solutions, a pioneer in providing health economic research, communications, and consulting services to the global pharmaceutical industry.
buyer: Arsenal Capital Partners
Arsenal is a leading private equity firm that specializes in investments in middle‐market specialty industrials and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds of $5.3 billion, and completed more than 45 platform investments. "
target: BresMed Health Solutions Ltd
BresMed is a health economic and outcomes research consultancy that provides health economic solutions to the global pharmaceutical industry. Established in 2006, BresMed has more than 150 staff across offices in the U.K., Ireland, the Netherlands, the U.S., and India.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/22/2020 via PR Newswire

Clarivate Analytics, will acquire Decision Resources Group

synopsis: Clarivate Analytics plc, a global leader in providing trusted insights and analytics, will acquire Decision Resources Group ("DRG"), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, from Piramal Enterprises Limited, part of global business conglomerate Piramal Group.
buyer: Clarivate Analytics (:$964.58)
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management. "
target parent: Piramal Group
target: Decision Resources Group
Decision Resources Group (DRG) is uniquely positioned to help healthcare businesses improve the lives of patients around the world by creating patient-centric commercial strategies that drive better outcomes and better access.
price ($mm)
$950
rev ($mm)
$207
EBITDA ($mm)
$48
EV / rev
4.6x
EV / EBITDA
20.0x
closed 8/16/2017 via PR Newswire

Decision Resources Group, acquired Context Matters

synopsis: Decision Resources Group announced that it has completed the acquisition of Context Matters, the innovative data technology start-up that developed a first-of-its-kind global market access integrated data platform.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Context Matters
Context Matters is led by a team with extensive experience in the pharma & biotech and financial & information sectors with deep operational familiarity of the issues facing the pharmaceutical industry and those following the industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/29/2016 via PR Newswire

Decision Resources Group, acquired Adaptive Software LLC

synopsis: Decision Resources Group (DRG) announced that it has acquired Adaptive Software. The company is a group of developers of market-leading pharmacy benefit and formulary management software platforms.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 15 offices in North America, Europe and Asia. "
target: Adaptive Software LLC
Adaptive Software, located in Kansas City, currently offers to health plans and Pharmacy Benefit Managers (PBMs) a suite of software solutions that streamlines formulary management, pharmacy networking, pricing, and pharmacy benefit design.
price ($mm)
$7.40
rev ($mm)
$3
EBITDA ($mm)
EV / rev
7.7x
EV / EBITDA
closed 5/14/2015 via PR Newswire

Decision Resources Group, acquired Healthcare Business Insights

synopsis: Decision Resources Group (DRG), a subsidiary of Piramal Enterprises Ltd., announced that it has acquired Healthcare Business Insights (HBI), a trusted provider of best practice research, training and services to more than 1,400 hospitals across the U.S. HBI's member-centric Academies enable hospitals to understand how to address critical issues.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Healthcare Business Insights
Healthcare Business Insights (HBI) is a leading provider of in-depth research and thoughtful insights across the core business functions found in hospitals and health systems nationwide. HBI's membership programs include Revenue Cycle, IT, Supply Chain and Cost & Quality.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2015 via PR Newswire

Decision Resources Group, acquired Activate Networks

synopsis: Decision Resources Group, a leading research and advisory company focused on high-value healthcare data, insights and analytics, announced that it acquired Activate Networks. Their analytics platform and suite of SaaS software applications enable healthcare/life sciences companies to unlock the commercial value of their customer networks.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Activate Networks
Activate Networks, Inc. is the leading provider of network analytics for healthcare/life sciences companies. Their analytics platform and suite of SaaS software applications enable healthcare/life sciences companies to unlock the commercial value of their customer networks.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/7/2014 via PR Newswire

Decision Resources Group, acquired Relay Technology Management

synopsis: Piramal Enterprises' Information Management Subsidiary, Decision Resources Group, one of the world's leading research and advisory firms focusing on high-value healthcare insights and analytics, announced that it acquired Relay Technology Management, a data analytics company focused on the life-sciences industry.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Relay Technology Management
Relay Technology Management is a life sciences business intelligence software provider founded in 2008 with one core belief: that enabling data-driven decision-making via objective, standard asset valuation and trend analytics will lead to increased efficiency in drug development.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/4/2012 via BusinessWire

Decision Resources Group, acquired Abacus International

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it has acquired Abacus International, a pioneer in evidence-based global market access solutions for many of the world’s leading healthcare companies.
buyer parent: Piramal Group
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Abacus International
Abacus International is unique in its provision of services throughout the lifecycle of a pharmaceutical or medical device. They can provide tailored solutions to overcome each hurdle of the product development process, from pre-launch though to market access.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 4/17/2012 via BusinessWire

Decision Resources Group, acquired Pinsonault Associates, LLC.

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, announced that it acquired Pinsonault, a leading provider in offering managed markets-specific business and training solutions to the pharmaceutical and biotech industries.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions. "
target: Pinsonault Associates, LLC.
Pinsonault is dedicated to and focused on delivering high quality, Managed Markets specific, business and training solutions within the pharmaceutical and biotech industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/25/2011 via BusinessWire

Decision Resources Group, acquired PharmaStrat, Inc.

synopsis: Decision Resources Group, one of the world’s leading research and advisory firms focusing on healthcare insights and analysis, has acquired PharmaStrat, the leading consulting and market research services firm focused on issues related to reimbursement and organized customer segments for biopharmaceutical manufacturers.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, insights, advisory services and consulting on important sectors of the healthcare industry. "
target: PharmaStrat, Inc.
PharmaStrat is the leading consulting and market research services firm focused on issues related to reimbursement and organized customer segments for biopharmaceutical manufacturers. It delivers strategic perspectives and market insight solutions that proactively address challenges and opportunity.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2010 via PR Newswire

Decision Resources, Inc., acquired BioTrends Research Group, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced that it acquired BioTrends Research Group, the leader in providing specialized, syndicated market research in clinically complex, small to mid-size pharmaceutical markets.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: BioTrends Research Group, Inc.
BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/17/2008 via PR Newswire

Decision Resources, Inc., acquired Manhattan Research, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced that it acquired Manhattan Research, a leading provider of access to physician and consumer opinions on the global healthcare market.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: Manhattan Research, Inc.
Manhattan Research is a healthcare market research and advisory services firm, bringing clarity to the market forces, trends, and impacts of physician and consumer use of information technology, including next generation digital media such as social networking, blogs, podcasts, and Web 2.0.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/17/2008 via Company Press Release

Decision Resources, Inc., acquired Fingertip Formulary

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare industry insight and analysis, announced that it acquired Fingertip Formulary, the leading provider of access to and insight into formulary data in the United States.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: Fingertip Formulary
Fingertip Formulary offers comprehensive formulary data covering commercial, Medicaid, Medicare, and PBM plans, among others, in the United States. Fingertip Formulary offers a variety of unique data and marketing solutions that provide access to and insight into formulary data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/19/2007 via PR Newswire

Decision Resources, Inc., acquired Arlington Medical Resources Inc.

synopsis: Berkery Noyes, the leading independent investment bank serving the media, information and technology markets, announces that it represented Arlington Medical Resources, Inc. in its sale to Decision Resources, Inc., a portfolio company of Providence Equity Partners, Inc. Terms of the transaction were not disclosed.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: Arlington Medical Resources Inc.
AMR is a privately held pharmaceutical market research firm headquartered in suburban Philadelphia. We have been serving the market research needs of the pharmaceutical & diagnostic imaging industries since 1988.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/20/2007 via

Decision Resources, Inc., purchased Life Sciences business from Wood Mackenzie

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced that it plans to acquire Wood Mackenzie's Life Sciences business.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
seller: Wood Mackenzie
Wood Mackenzie has been providing its unique range of consulting services and research products to the Energy and Life Sciences industries for over 30 years. Our market proposition is based on our ability to provide forward- looking insight that enables our clients to make better business decisions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/10/2007 via

Providence Equity Partners Inc., acquired Decision Resources, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, announced today that Providence Equity Partners, a leading private equity firm with more than $21 billion under management, will acquire majority control of the Company.
buyer: Providence Equity Partners Inc.
Providence Equity Partners Inc. is a private investment firm specializing in equity investments in communications and media companies around the world. The principals of Providence Equity manage funds with approximately $21 billion in equity commitments. "
target parent: Boston Ventures Management, Inc.
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/2/2006 via PR Newswire

Decision Resources, Inc., acquired Millennium Research Group

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare industry insight and analysis, announced today that it acquired Millennium Research Group, the global authority on medical technology market intelligence.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: Millennium Research Group
Millennium Research Group is a leading provider of strategic information to the healthcare sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the Company provides its clients with the benefits of its specialized industry expertise through published reports.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/22/2005 via BusinessWire

HCPro, acquired HealthLeaders, Inc.

synopsis: HCPro, Inc. today announced it has significantly broadened its healthcare publishing lines by acquiring HealthLeaders Media from Decision Resources, Inc. The acquisition includes the monthly HealthLeaders magazine, several general healthcare business email publications, live events and a state-specific healthcare business news service.
buyer parent: The Riverside Company
buyer: HCPro
HCPro is a leading provider of integrated information, education, training, and consulting products and services in the vital areas of healthcare regulation and compliance. The company's mission is to meet the specialized informational, advisory, and educational needs of the healthcare industry. "
target parent: Boston Ventures Management, Inc.
target: HealthLeaders, Inc.
HealthLeaders is a leading multi-platform media company dedicated to meeting the business information needs of healthcare executives and professionals.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/6/2004 via PR Newswire

Boston Ventures Management, Inc., Castanea Partners, acquired Decision Resources, Inc.

synopsis: Castanea Partners and Boston Ventures Limited Partnership VI today announced the recapitalization of Decision Resources, Inc., with a total transaction value of $58 million. The Waltham, Massachusetts-based company is best known for its therapeutically-focused analyses of global pharmaceutical and biotechnology markets.
buyer: Boston Ventures Management, Inc.
buyer: Castanea Partners
Boston Ventures Management, LLC is a private equity firm that has been an active investor and financial partner to management teams in the media, entertainment, publishing and information and communications sectors since 1983, earning the firm a franchise position in the private equity community. "
target: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit.
price ($mm)
$58
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/22/2020 via PR Newswire

Clarivate Analytics, will acquire Decision Resources Group

synopsis: Clarivate Analytics plc, a global leader in providing trusted insights and analytics, will acquire Decision Resources Group ("DRG"), a premier provider of high-value data, analytics and insights products and services to the healthcare industry, from Piramal Enterprises Limited, part of global business conglomerate Piramal Group.
buyer: Clarivate Analytics (:$964.58)
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management. "
target parent: Piramal Group
target: Decision Resources Group
Decision Resources Group (DRG) is uniquely positioned to help healthcare businesses improve the lives of patients around the world by creating patient-centric commercial strategies that drive better outcomes and better access.
price ($mm)
$950
rev ($mm)
$207
EBITDA ($mm)
$48
EV / rev
4.6x
EV / EBITDA
20.0x
closed 6/11/2012 via BNC Analysis

Piramal Healthcare Limited, acquired Decision Resources Group

synopsis: Piramal Healthcare Limited has completed its previously announced acquisition of Decision Resources Group, a US based company in the healthcare information segment. Decision Resources Group is a cohesive portfolio of companies that offers best in class, high-value information and insights on important sectors of the healthcare industry.
buyer parent: Piramal Group
buyer: Piramal Healthcare Limited
With assets across North America, Europe and Asia, Piramal Healthcare is one of the largest pharmaceutical custom manufacturing companies across the world. It has significant presence in the global critical care space with sales of anesthesia products to over 100 countries. "
target parent: Providence Equity Partners Inc.
target: Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. The top biopharmaceutical, medical technology and managed care companies rely on the Company’s predictive analytics to make fully informed decisions.
price ($mm)
$635
rev ($mm)
$160
EBITDA ($mm)
EV / rev
4.0x
EV / EBITDA
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/22/2005 via BNC Analysis

Clinical Data, Inc., will acquire Genaissance Pharmaceuticals, Inc.

synopsis: Clinical Data Inc. announced Tuesday that it will acquire Genaissance Pharmaceuticals in an all-stock transaction valued at $56 million. Genaissance shareholders will own 40 percent of the combined company when the deal closes sometime in the fourth quarter.
buyer: Clinical Data, Inc. (CLDA:$0.00)
Clinical Data, Inc. provides a full range of products and services to the growing domestic Physician Office Laboratory market and to smaller laboratories internationally & also provides a complete range of products and services for the Physician Office Laboratory and hospital laboratory market. "
target: Genaissance Pharmaceuticals, Inc.
Genaissance is a world leader in the discovery and use of human gene variation for the development of a new generation of DNA-based diagnostic and therapeutic products. Genaissance markets its technology, clinical development skills and Pharmacogenomic support services to the pharmaceutical industr
price ($mm)
$56
rev ($mm)
$21
EBITDA ($mm)
EV / rev
2.7x
EV / EBITDA
closed 10/26/2010 via Market Wire

Unity Management Group, Inc, acquired Metropolitan Computer Corporation

synopsis: Unity Management Group, Inc announced that it has successfully completed the acquisition of Metropolitan Computer Corporation (MCC/ Legacy).
buyer: Unity Management Group, Inc (US:UYMG:$0.00)
Unity Management Group is a health resource company, which provides quality physician practice management services, that offer high value, and significant return, through its three subsidiary companies. United Healthcare Solutions, Unity Technologies Inc., and United Business Services. "
target: Metropolitan Computer Corporation
Metropolitan Computer Corporation (MCC/ Legacy) designs, engineers, markets, and services instrumentation equipment and software systems for increased efficiency within the pharmaceutical industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/2/2004 via BusinessWire

Apogent Technologies, Inc. merged with Fisher Scientific International Inc.,

synopsis: Fisher Scientific International Inc. (NYSE: FSH) today completed its approximately $4.0 billion merger with Apogent Technologies Inc. (formerly trading as NYSE: AOT), providing Fisher Scientific with a $1.1 billion footprint in the high-growth life-science market.
buyer parent: Thomas H. Lee Partners, L.P.
buyer: Fisher Scientific International Inc.
Fisher Scientific International, Inc. provides products and services to the scientific research and clinical laboratory markets. It operates in three segments: Scientific Products and Services, Healthcare Products and Services, and Laboratory Workstations. The Scientific Products and Services segmen"
target: Apogent Technologies, Inc.
Apogent Technologies Inc. is a developer and manufacturer of value-added products for the clinical and research markets. Over 80% of the Company's products are consumables. Apogent's operating subsidiaries manufacture most of their products in approximately 80 facilities worldwide. The Company's cu
price ($mm)
$3,991
rev ($mm)
$1,118
EBITDA ($mm)
$313
EV / rev
3.6x
EV / EBITDA
12.7x
announced 3/8/2016 via PR Newswire

Nordic Capital, will acquire ERT

synopsis: Genstar Capital, a leading private equity firm focused on the healthcare, software, financial services, and industrial technology industries, announced the sale of ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, to Nordic Capital Fund VIII.
buyer: Nordic Capital
Nordic Capital is a leader in Nordic private equity investments, and now has an enviable reputation in investment and portfolio management. Since launching in 1989, Nordic Capital funds have delivered outstanding returns for our investors. "
target parent: Genstar Capital LLC
target: ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions.
price ($mm)
rev ($mm)
$300
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 7/3/2012 via PR Newswire

Genstar Capital LLC, acquired ERT

synopsis: ERT, a global technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations, announced that Genstar Capital, LLC, has completed its acquisition of the company in a take-private transaction.
buyer: Genstar Capital LLC
Genstar Capital LLC has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries. "
target: ERT
ERT is a global technology-driven provider of health outcomes research services and customizable medical devices supporting biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.
price ($mm)[EV]
$395 [$370]
rev ($mm)
$194
EBITDA ($mm)
$42
EV / rev
1.9x
EV / EBITDA
9.0x
announced 3/6/2012 via PR Newswire

CareFusion Corporation, will acquire PhACTs, LLC.

synopsis: CareFusion Corporation announced an agreement to acquire PHACTS, LLC, a Seattle-based technology and consulting company that helps hospital pharmacies better manage inventory, reduce pharmaceutical costs and streamline operations. Terms of the deal were not disclosed.
buyer: CareFusion Corporation (CFN:$3,598.00)
CareFusion Corporation is a global corporation serving the health care industry with products and services that help hospitals measurably improve the safety and quality of care. "
target: PhACTs, LLC.
PHACTS was formed to serve Health Systems with multiple hospitals and/or clinics, doctors' offices, surgery centers and other locations, which need to account for and provide medications and pharmacy supplies across their network.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Decision Resources Group


read more

Decision Resources Group

Decision Resources Group

Dymaxium, Inc.

Vidal Group

MedicalDirector

Avalere Health LLC

Abacus International

Edital

Prous Science

Infinata, Inc.

Pharmaspectra

SpringerProtocols

ERT

NHiS Ltd

ERT

TargetRx, Inc.

AlphaImpactRx, Inc

ImpactRx, Inc.

Context Matters

BresMed Health Solutions Ltd

read more

Decision Resources Group

Context Matters

Adaptive Software LLC

Healthcare Business Insights

Activate Networks

Relay Technology Management

Abacus International

Decision Resources Group

Pinsonault Associates, LLC.

PharmaStrat, Inc.

BioTrends Research Group, Inc.

Manhattan Research, Inc.

Fingertip Formulary

Arlington Medical Resources Inc.

Wood Mackenzie

Decision Resources, Inc.

Millennium Research Group

HealthLeaders, Inc.

Decision Resources, Inc.

read more

Decision Resources Group

Decision Resources Group

read more

AAIPharma Services

Genaissance Pharmaceuticals, Inc.

Metropolitan Computer Corporation

Apogent Technologies, Inc.

ERT

ERT

PhACTs, LLC.

Geography
Matching Companies
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3.com
M3.com
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries.
year
2019
rev ($mm)
$1,015.17
EBITDA ($mm)
$288.13
EBIT ($mm)
$275.64
Net Income ($mm)
$175.78
Employees
5165
  • drill down
  • watch
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3, Inc.
M3 Inc. represents the three Ms of Medicine, Media, and Metamorphosis. Their company was founded with the goal of changing the world of medicine through making full use of the power of the Internet.
year
2019
rev ($mm)
$1,127.03
EBITDA ($mm)
$319.84
EBIT ($mm)
$286.78
Net Income ($mm)
$193.56
Employees
6024
  • drill down
  • watch
Ticker: TSE:6095
 
 
 
 
 
 
 
 
MedPeer,Inc.
MedPeer,Inc.
MedPeer provides appropriate services at every stage of the clinical process physicians are involved in day-to-day clinical operation. Drug Evaluation provides detailed peer reviews of prescription drugs, and Meet the Experts allows members to consult expert physicians in specific therapeutic areas.
year
2016
rev ($mm)
$9.13
EBITDA ($mm)
$0.94
EBIT ($mm)
$0.39
Net Income ($mm)
$0.20
Employees
44
  • drill down
  • watch
Ticker: JNJ
 
 
 
 
 
 
 
 
Johnson & Johnson
Johnson & Johnson
Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics.
year
2019
rev ($mm)
$81,325.00
EBITDA ($mm)
$27,998.00
EBIT ($mm)
$21,066.00
Net Income ($mm)
$16,332.00
Employees
135100
  • drill down
  • watch
Ticker: COV
 
 
 
 
 
 
 
 
Covidien
Covidien
Tyco Healthcare became Covidien and began independently trading on the New York and Bermuda Stock Exchanges on July 2, 2007, marking its debut as an independent diversified global healthcare products company.
year
2010
rev ($mm)
$10,429.00
EBITDA ($mm)
$2,628.00
EBIT ($mm)
$2,139.00
Net Income ($mm)
$1,632.00
Employees
41500
  • drill down
  • watch
Ticker: MRK
 
 
 
 
 
 
 
 
Merck & Co., Inc.
Merck & Co., Inc.
Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they deliver health solutions.
year
2020
rev ($mm)
$48,081.00
EBITDA ($mm)
$19,058.00
EBIT ($mm)
$15,735.00
Net Income ($mm)
$10,147.00
Employees
71000
  • drill down
  • watch
Ticker: ASX:AVX
 
 
 
 
 
 
 
 
Avexa Limited
Avexa is a biotechnology company dedicated to the discovery and development of new drugs to treat serious infectious diseases, particularly Human Immunodeficiency Virus (HIV). They are based in Australia.
year
2015
rev ($mm)
$0.24
EBITDA ($mm)
($1.45)
EBIT ($mm)
($1.46)
Net Income ($mm)
Employees
5
  • drill down
  • watch
Ticker: ENXTPA:BIM
 
 
 
 
 
 
 
 
bioMérieux S.A.
bioMérieux S.A.
A world leader in the field of in vitro diagnostics for 50 years, bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety.
year
2015
rev ($mm)
$1,996.55
EBITDA ($mm)
$404.73
EBIT ($mm)
$278.41
Net Income ($mm)
$155.44
Employees
9258
  • drill down
  • watch
Ticker: ENXTPA:DIM
 
 
 
 
 
 
 
 
Sartorius AG
Sartorius AG
Sartorius is a international pharmaceutical and laboratory equipment supplier. With their innovative products and services, they are helping their customers across the entire globe to implement their complex and quality-critical biomanufacturing and laboratory processes reliably and economically.
year
2016
rev ($mm)
$1,121.72
EBITDA ($mm)
$299.20
EBIT ($mm)
$257.20
Net Income ($mm)
$163.92
Employees
4590
  • drill down
  • watch
Ticker: XTRA:SBS
 
 
 
 
 
 
 
 
Stratec SE
Stratec SE
STRATEC SE designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers complex consumables for diagnostic and medical applications.
year
2019
rev ($mm)
$240.89
EBITDA ($mm)
$38.57
EBIT ($mm)
$21.94
Net Income ($mm)
$15.69
Employees
1223
  • drill down
  • watch
Ticker: CAH
 
 
 
 
 
 
 
 
Cardinal Health, Inc.
Cardinal Health, Inc.
Cardinal Health, Inc. improves the cost-effectiveness of the health care industry. Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability.
year
2018
rev ($mm)
$141,935.00
EBITDA ($mm)
$2,870.00
EBIT ($mm)
$1,860.00
Net Income ($mm)
Employees
50200
  • drill down
  • watch
Ticker: FMS
 
 
 
 
 
 
 
 
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA
As a vertically integrated company, we offer products and services for the entire dialysis value chain. The highest medical standards are our benchmark.
year
2009
rev ($mm)
$11,247.48
EBITDA ($mm)
$2,212.68
EBIT ($mm)
$1,755.60
Net Income ($mm)
$891.14
Employees
72812
  • drill down
  • watch
Ticker: BDX
 
 
 
 
 
 
 
 
Becton, Dickinson and Company
Becton, Dickinson and Company
Becton, Dickinson and Company (BD) is a leading medical technology company. BD’s innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research.
year
2012
rev ($mm)
$7,708.38
EBITDA ($mm)
$1,970.62
EBIT ($mm)
$1,577.89
Net Income ($mm)
$1,169.93
Employees
  • drill down
  • watch
Ticker: FAGR
 
 
 
 
 
 
 
 
Fagron
Fagron
Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding worldwide. Fagron offers Fagron Compounding Essentials, Fagron Trademarks and Fagron Compounding Services to pharmacies and hospital pharmacies in 30 countries.
year
2014
rev ($mm)
$473.30
EBITDA ($mm)
$113.50
EBIT ($mm)
$96.32
Net Income ($mm)
$17.17
Employees
1902
  • drill down
  • watch
Ticker: ABT
 
 
 
 
 
 
 
 
Abbott Laboratories
Abbott Laboratories
Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.
year
2009
rev ($mm)
$30,764.71
EBITDA ($mm)
$8,220.25
EBIT ($mm)
$6,130.74
Net Income ($mm)
$5,745.84
Employees
73000
  • drill down
  • watch
Ticker: SYK
 
 
 
 
 
 
 
 
Stryker Corporation
Stryker Corporation
Stryker Corporation is one of the world's leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties.
year
2016
rev ($mm)
$10,062.00
EBITDA ($mm)
$2,717.00
EBIT ($mm)
$2,312.00
Net Income ($mm)
$1,617.00
Employees
27000
  • drill down
  • watch
Ticker: HOLX
 
 
 
 
 
 
 
 
Hologic, Inc.
Hologic, Inc.
Hologic is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of state-of-the-art digital imaging technology for general radiography and mammography applications.
year
2011
rev ($mm)
$1,789.35
EBITDA ($mm)
$595.38
EBIT ($mm)
$290.64
Net Income ($mm)
$157.15
Employees
5019
  • drill down
  • watch
Ticker: ASX:SFP
 
 
 
 
 
 
 
 
Safety Medical Products Ltd
Safety Medical Products Limited has various patents and registered trademarks associated with the SecureTouch syringe in regions and countries including Europe, the United States of America, Africa, Australia and New Zealand.
year
2013
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
($0.77)
Net Income ($mm)
Employees
  • drill down
  • watch